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Summary Questions
1. What is the new aspect of your work?
This work discusses and reviews several potential treatments for management of
patients with frequent vascular occlusive crises associated with sickle cell
disease other than opioids and hydroxyurea. These new treatments either have
been approved or are in development.

2. What is the central finding of your work?
As understood, a vaso-occlusive crisis in patients with sickle cell disease is a
multifactorial process characterized by inflammation, adhesion, and multicellular
aggregation of sickled red blood cells, endothelial cells, platelets, and other blood
cells, resulting in vaso-occlusion and acute severe pain. Prevention of onset
and/or reduction in frequency of pain crises, especially in those at higher risk,
should be considered foremost, as opposed to management protocols that treat
pain with opioid administration.

3. What is (or could be) the specific clinical relevance of your work?
While management protocols to abort or ameliorate vaso-occlusive crises by
administration of opioids have been developed and are widely in use, opioid
medication does not address the underlying disease processes, and may lead to
hyperalgesia, dependence, and tolerance. Prevention of pain associated with
these crises is a preferred approach whenever possible. Studies have shown that
supplementation with L-glutamine decreases endothelial cell adhesion,
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suggesting that it may be useful for prevention of vaso-occlusive crises; this drug
has been approved by the US Food and Drug Administration (FDA) in 2017 to
reduce the complications of sickle cell disease in adult and pediatric patients 5
years of age and older. Additionally, the drug crizanlizumab was approved by the
FDA in 2019 to reduce the frequency of crises in patients at least 16 years of
age. Other drugs are in clinical development as well. Education of hematologists
and others who work in the field of sickle cell disease about these new agents
should lead to improved protocols for patients with sickle cell disease, with an
expected outcome of a reduction in vaso-occlusive crises.
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Abstract [114 words; 200-word limit]
Early diagnosis, treatment, and prevention of a vaso-occlusive crisis (VOC) is
critical to the management of patients with sickle cell disease. It is essential to
differentiate between VOC-associated pain and chronic pain, hyperalgesia,
neuropathy, and neuropathic pain. The pathophysiology of VOCs includes
polymerization of abnormal sickle hemoglobin, inflammation, and adhesion.
Hydroxyurea, L-glutamine, and crizanlizumab have been approved by the US
Food and Drug Administration for reducing the frequency of VOCs; the European
Medicines Agency (EMA) has approved only hydroxyurea. Other novel
treatments are in late-stage clinical development in both the United States and
the European Union. Development of agents for prevention and treatment of
VOCs should be driven by our understanding of its pathophysiology.
Keywords: sickle cell disease, vaso-occlusive crisis, hydroxyurea, L-glutamine,
voxelotor, crizanlizumab
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Introduction
Sickle cell disease (SCD) is the most common hemoglobinopathy, with
approximately 300,000 new cases each year and millions of patients affected
globally (1). In the United States, there are more than 230,000 hospital
admissions related to SCD annually at an economic cost of $2.4 billion (2). Acute
episodes of pain, also commonly referred to as sickle cell pain crises, or vasoocclusive crises (VOCs), are not only the primary presenting morbidity
associated with SCD, but also the cause of hospitalization in approximately 95%
of cases (3). Furthermore, the frequency of VOCs, along with acute chest
syndrome (ACS), is the most common predictor of death in patients with SCD
(4). Recurrent episodes have a significant impact on quality of life (5), such that
the incidence of pain may have a greater impact on quality of life than cumulative
organ damage (6).

The pain associated with VOC is often described as sudden in onset, throbbing,
and sharp (5-). Common sites of pain include the lower back, joints, and
extremities. Vaso-occlusive crisis is often preceded by a prodromal phase of 1–2
days, with pain peaking on Day 3 and lasting until Day 6 or 7 before resolving (5).
The average hospital stay is approximately 9–11 days in adults (5). In addition to
the pain associated with VOC, there are a number of clinical consequences.
Acute chest syndrome, hepatic and renal involvement, cerebrovascular accident,
and multi-organ failure resulting in death can develop in association with VOCs
(7–9). Acute chest syndrome occurs in 10%–20% of hospitalized patients with
5

SCD, usually manifesting 1–3 days after admission for a severe VOC and can, in
some cases, progress rapidly to acute respiratory failure and death (10). Thus,
identification, treatment, and prevention of VOCs could significantly impact the
natural history of the disease. The objective of this review is to discuss the
pathophysiology, diagnosis, and management of VOC, and to distinguish
between VOC and other causes of pain in patients with SCD.

Mechanisms of VOC
In order to accurately diagnose, predict, or prevent the onset of VOC and
associated pain and other sequelae, it is necessary to understand the underlying
mechanisms. Chronic vascular inflammation causes activation of endothelial and
blood cells leading to release of macrophages, mast cells, and platelets,
multicellular adhesion, and activation of nociceptors, resulting in vaso-occlusion
and VOC (11,12). Vaso-occlusion is a multifactorial process involving not only
occlusion of small blood vessels by sickled red blood cells (RBCs) and adherent
blood cells, but also large-vessel intimal hyperplasia, thrombosis, and bone
marrow fat embolization (13), leading to hypoxia, ischemia, and tissue damage
and inflammation (4,14–16). It is this combination of hypoxia/reperfusion injury,
ischemic tissue damage, and inflammation that makes SCD pain unique (4).

Polymerization
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Polymerization of deoxygenated sickle hemoglobin leads to decreased
deformability of RBCs, with deformability reduced early in VOC (17,18).
Counterintuitively, high levels of RBC deformability during the recovery phase of
a painful VOC has been shown to be predictive of new painful crises; this may be
due to the fact that sickled RBCs with the highest deformability are the most
adherent (17,18).

Adhesion
Vaso-occlusive crises are believed to occur because of adherence of sickled
RBCs to the vascular endothelium, adherent leukocytes, and platelets in small
blood vessels. This multicellular adhesion, rather than changes in RBC
morphology per se, is now thought to be the trigger for VOC, and has been
shown in animal models to lead to initiation of VOC (19). Accumulation of sickled
RBCs and other adherent cells may contribute to vaso-occlusion in smaller
vessels in the absence of an inflammatory trigger (17). Interaction of a number of
adhesion molecules has been implicated in SCD, including α4β1 integrin, CD36
expression on sickle cell versus normal erythrocytes, basal cell adhesion
molecule/Lutheran protein, and endothelial vascular cell adhesion molecule-1
(VCAM-1) (19,20).

P-selectin is another adhesion molecule that is implicated in inflammation,
coagulation, and atherosclerosis, and appears to be particularly important in SCD
7

(21). P-selectin is expressed on the surface of both endothelial cells and
platelets, and has a role in the adhesion, rolling, and capture of blood cells (21–
23). Activated platelets bind to neutrophils in a P-selectin-dependent manner to
form aggregates, and increased expression of P-selectin on endothelial cells
promotes leukocyte adhesion, together contributing to development of VOC (24).
Possible triggers described for this process include inflammation, stress,
increased viscosity, decreased flow, and hemolysis (15).

Inflammation
The inflammatory chemokine CXCL1, which acts as a neutrophil
chemoattractant, has been identified as a critical mediator of VOC in humanized
SCD mice (25), and neutrophil activation accompanied by an acute inflammatory
response has been associated with VOC in patients who experience subsequent
ACS (26). Together, sickled RBCs, activated endothelial cells, neutrophils,
leukocytes, and monocytes create a pro-inflammatory and pro-aggregatory
environment (15,27). Ischemia-reperfusion injury secondary to microvascular
occlusions promotes chronic inflammation through increased oxidant production
and increased adhesion of leukocytes, which further contributes to vasoocclusion and tissue damage (28). Inflammatory mediators TGF-β and IL-17
have been shown to be significantly increased in patients with SCD at steady
state compared with controls; TNF-α, IL-6, and IL-8 are also significantly elevated
compared with controls in patients with SCD and VOCs (29).
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Distinguishing Between VOC and Other Types of Pain in SCD
The pain associated with VOC is typically acute and severe, often requiring
treatment with parenteral opioids (3). However, it is important to distinguish VOC
pain from other pain syndromes commonly seen in SCD. For instance, many
patients with SCD suffer from chronic pain as a result of bone infarction,
avascular necrosis of the femoral or humeral head, leg ulcers, and chronic
osteomyelitis. Some patients also experience intractable chronic pain without
evident pathology (5,30).

Chronic pain in SCD has been defined as ongoing pain that is present on most
days over 3–6 months in a single or multiple locations (5,31). Chronic pain is
usually treated with long-acting or controlled-release opioids and does not
require hospitalization unless severe or associated with an acute crisis, or if it is
associated with severe infection as may happen with leg ulcers (5,32). Pediatric
patients with SCD are more likely to be pain free between VOCs compared with
adult patients with SCD; with increasing age, mild or moderate pain between
crises becomes more common, complicating diagnosis and management (5).
Although acute pain is usually thought to be a consequence of VOC, it is also
possible that pain itself may trigger vasoconstriction, leading to full-scale VOC
9

(33). It is estimated that 47% of adult patients with SCD in the United States take
short-acting opioids and 27% take both short- and long-acting opioids, although
the median daily dose of opioids is relatively low at 6.1 mg oral morphine
equivalents (33). A fraction of patients also take non-steroidal anti-inflammatory
drugs (NSAIDs) (33).

Neuropathic pain is usually regarded as chronic, and is usually described as
numb, tingling, lancinating, spontaneous, shooting, or paroxysmal in nature, and
may be associated with a sensation of pins and needles, hyperalgesia, and
allodynia (5). This is in contrast to the pain associated with VOC, which is
described as pounding, cutting, gnawing, or like a generalized toothache (5).
Neuropathic pain is quite common in patients with SCD, with 37% having
evidence of neuropathic pain in one study (34,35). It is therefore critical to
differentiate between neuropathic pain and acute and chronic pain seen in these
patients. Neuropathic pain has also been shown to correlate with older age
(34,35). It is important to note that neuropathy and neuropathic pain are not the
same. Neuropathic pain is usually defined as pain arising as a direct
consequence of a lesion or disease affecting the somatosensory system (36).
This type of pain usually occurs in concert with VOC and resolves after the crisis
ends (37). Drugs typically used for neuropathic pain, including gabapentin,
pregabalin, and amitriptyline, have not been systematically studied in patients
with SCD, but preliminary studies and case reports have suggested that they
may have some efficacy, including reducing the frequency of VOCs (38–40). A
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number of patient-reported outcome (PRO) scales, including the McGill Pain
Questionnaire and PAINReportIt®, have been used to diagnose neuropathic pain
in SCD (37). Neuropathy, such as peripheral neuropathy, also occurs in SCD,
with mental nerve neuropathy most commonly associated with VOC (5,34).
Although neuropathy is not always associated with pain, it may occur as a result
of tissue damage to vessels and nerves following VOC.

Differential Diagnosis of VOC
When diagnosing VOC, the most important step is to differentiate it from acute
flares of chronic pain that are often of unknown origin, but could be related to
orthopedic complications of SCD, including bone infarction and avascular
necrosis (5,30). Diagnosis of VOC in children is complicated by the fact that VOC
affecting the bone is the most common acute clinical manifestation of SCD in this
population (41). Vaso-occlusive crisis may also be confused with the much less
frequently occurring osteomyelitis, which can be an acute or chronic
inflammatory process caused by infection with pyogenic organisms due to
impaired immune function and functional asplenia, leading to infection of the
bone. Osteomyelitis is characterized by localized pain, tenderness, and swelling
affecting a single site and a limited range of motion, and/or prolonged fever and
pain. While the number of days of fever and pain prior to admission, as well as
increased C-reactive protein levels and erythrocyte sedimentation rates, are
considered to be key differentiators by some, often it is difficult to differentiate the
two conditions (41,42).
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Neuropathic pain and hyperalgesia can also be difficult to distinguish from VOC.
While hyperalgesia is a signature of neuropathic pain, it can also occur due to
prolonged opioid use (5). Opioid-induced hyperalgesia differs from tolerance in
that increasing the opioid dose to manage pain paradoxically increases pain
sensitivity, results in higher pain scores, and is accompanied by allodynia (43).

It may also be necessary to differentiate ACS from VOC manifested in the
pulmonary system (44). Both present with fever, shortness of breath, chest pain,
and leukocytosis. A new infiltrate on chest X-ray is diagnostic of ACS, which may
appear normal early in an ACS episode (45). However, pain usually precedes
onset of ACS, with ACS occurring about 3 days after the onset of VOC (9).

Managing Pain Crises in SCD
The primary approach to management of ongoing VOCs is pain control.
Guidelines have been provided by the National Heart, Lung, and Blood Institute
(NHLBI) regarding the management of acute and chronic pain in SCD, including
pain associated with VOC (45). The core elements of management of VOC
include initiation of individualized opioid analgesia (ideally within 30 minutes),
determining the most appropriate route of analgesic administration (oral,
intranasal, subcutaneous, or intravenous), choosing an adequate starting dose
(0.1 mg/kg morphine or 0.015 mg/kg hydromorphone), and repeating
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administration frequently (every 15–30 minutes) until pain improves (30,45–47). If
possible, an individual’s prior history of pain control requirements during VOC
should be used to determine appropriate dosing. In a recent phase 3 study,
patient-specific dosing protocols, based in part on patient history, provided for
better outcomes than a standard weight-based approach (48). Patient-controlled
analgesia can also be considered. However, certain studies have indicated that
this is less effective than other forms of pain control, resulting in a longer length
of stay by up to 8 days in patients aged 18–30 years and 13 days in those older
than 30 years (49).

Acetaminophen (paracetamol) and NSAIDs are widely used adjuvant therapies
with opioids, not only because they can help to reduce the opioid requirement
and reduce associated adverse events, but also because VOC is associated with
increased inflammatory markers, including prostaglandin (50). This is of interest
because the anti-inflammatory and analgesic effects of NSAIDs are mediated via
their inhibition of cyclooxygenase enzymes that convert arachidonic acid to
prostaglandin (51). In patients with VOCs associated with mild to moderate pain,
NSAIDs can be continued in place of opioids in patients who report pain relief
with this class of drugs (48). However, a randomized controlled trial indicated that
the NSAID ketoprofen had no additional effect when given in combination with
morphine (52). Care must be taken with use of NSAIDs in patients with SCD as
some patients may have contraindications for their use. For example, acute renal
failure may occur in subjects with chronic sickle nephropathy or other chronic
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kidney diseases when exposed to NSAIDs (45). Other areas of concern include
gastrointestinal and cardiovascular effects, and hypersensitivity caused by drug
allergy or due to biochemical processes linked to arachidonic acid metabolism
(51,53). In addition, prostaglandins have a wide variety of effects, including
induction of platelet aggregation, vasoconstriction and vasodilation, and
regulation of circadian rhythms, reproduction, and homeostasis, that could be
affected by NSAID use in this population (51). For patients with SCD with
evidence of, or at risk of, end-organ damage, use of NSAIDs may be
contraindicated, especially in patients with serum creatinine ≥1.0 mg/dL (45).

Potential adjuvant treatments include hydration, laxatives, antihistamines,
antiemetics, intravenous fluids, and oxygen if the patient is hypoxic, and less
commonly anxiolytics or non-pharmacologic approaches such as massage,
acupuncture, yoga, and meditation (30,44,46,54). Patients, especially children,
who are experiencing emerging pain are advised to hydrate and take NSAIDs at
home, provided there are no contraindications.

Recent studies have utilized mechanistic therapies to manage VOCs. The
investigational pan-selectin inhibitor rivipansel was studied in a prospective,
randomized, placebo-controlled phase 2 trial in patients experiencing VOCs.
Although not statistically significant, the median time to resolution of VOC was
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48% shorter than with placebo (69.6 hours vs 132.9 hours, respectively) (55). A
phase 3 trial is ongoing (ClinicalTrials.gov identifier: NCT02187003).

Prediction of VOC
Various predictive factors should heighten vigilance in monitoring for VOC, and
may be an indication for more aggressive management. For example, higher
levels of fetal hemoglobin may be protective against VOC and other pathological
consequences of SCD due to its interfering with polymerization of sickle
hemoglobin during the sickling process (56,57), and are also inversely related to
mortality (4). In addition, some patients have reported symptoms of numbness,
paresthesia, or aches before onset of VOC. In one study, 58% of patients with
SCD reported these symptoms 1–2 days before VOC, suggestive of a prodromal
phase (58).

Triggers of VOC
Many patient-related and environmental factors have been shown to be risk
factors for VOC, and may also lead to hyperalgesia (Table 1) (46,59). Patient
factors include hypoxia, infection, fever, acidosis, dehydration, pregnancy,
menstruation, and obstructive sleep apnea; pain itself can also precipitate painful
crises. Anxiety, depression, alcohol consumption, and physical exhaustion can
also trigger onset of VOC. In addition, comorbidities such as sarcoidosis,
diabetes, cholecystitis, and herpes can lead to pain crises. It has been suggested
15

that these triggers may actually cause pain crises due to a link between the
autonomic nervous system (ANS) and VOC (59). Perturbations in the ANS in
response to these triggers may cause ANS-mediated vasoconstriction, tipping
the balance from steady state towards VOC. A recent study using mathematical
models of biophysical markers indicated that markers relating to increased blood
pressure were involved in pain-induced vasoconstriction (60). These markers
may allow for characterization of disease severity and risk of VOC, based on the
underlying physiology rather than genotype.

Environmental factors such as exposure to extremes of temperature and higher
wind speed have also been identified as triggers for VOC (46,59) In one study,
colder temperatures and higher wind speed were associated with a higher
incidence of VOC in children under age 18 years (61). The average monthly pain
score was also significantly higher in more humid months.

Biomarkers of VOC
Some blood parameters have been associated with severity of SCD. As already
discussed, neutrophils have a key role in the pathogenesis of VOC (27). Higher
neutrophil counts have been shown to correlate with more severe disease,
including earlier death, and increased incidence of silent brain infarcts,
hemorrhagic stroke, and ACS (26). Although platelet counts have not
consistently been shown to be associated with the frequency or severity of
16

VOCs, platelet hyperactivity has been found to be increased during VOC. Plasma
levels of platelet factors 3 and 4 are increased in patients with SCD at steady
state and are even higher during VOC (62). Notably, patients with SCD are
capable of making platelet factor 3 available for coagulation activity, suggesting
that this may play a role in VOC (63). Papadimitriou et al suggested that platelet
inhibitors may have a role in prevention of VOC (62). Levels of extracellular
hemoglobin may also play a role in the development of VOC. Hemolysis resulting
in release of excessive amounts of hemoglobin is a signature of SCD.
Extracellular hemoglobin forms a complex with haptoglobin, but once the
capacity of haptoglobin for hemoglobin is surpassed, excess extracellular
hemoglobin can cause further complications (63). Unbound extracellular
hemoglobin in turn consumes the endogenous vasodilator nitric oxide, resulting
in vasoconstriction and systemic and pulmonary hypertension (63). This
hemoglobin also inhibits the cleavage of von Willebrand factor multimers, which
then accumulate in the plasma and bind to platelets or sickled/fragmented
erythrocytes to promote cell adhesion, leading to VOC (63). A recent study in
Nigeria found that higher hemoglobin levels, platelet and neutrophil counts, as
well as avascular necrosis and leg ulcers were all significantly associated with a
higher incidence of VOC (64). A number of other metrics also have been shown
to be predictive of the severity of VOC. For example, high levels of lactate
dehydrogenase in serum have been associated with a severe evolution of VOC,
especially in patients without ACS (65).
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A number of serum inflammatory markers potentially associated with VOC have
been identified. However, increases in these markers are typically observed once
a pain event has already begun, and therefore are connected to crisis severity
rather than being predictive of onset. One report suggested that VOC occurs due
to an imbalance in pro- and anti-inflammatory mechanisms associated with IL-10
signaling (66). This study found that reduced IL-10 secretion was associated with
an increased risk of VOC, possibly due to its effect on the pro-inflammatory
cytokine TNFα. However, because of the design of the study, it is not possible to
distinguish if this was a consequence rather than a predictor of VOC. Another
study suggested that levels of soluble CD163 >1400 ng/mL were predictive of
VOC and pulmonary hypertension (67).

Elevated levels of serum fractal kinase and Fkn gene expression in patients with
SCD at steady state and during VOC indicate that it may be important in acute
inflammation during crises (68) In fact, it has been shown that serum fractal
kinase is elevated in patients with the highest frequency of VOCs and may be
important in recurrent episodes. In addition, the potent inflammatory mediator
secretory phospholipase A2 has been shown to be elevated in patients with
VOCs who go on to develop ACS, and could be used to predict ACS
development, and hence identify candidates for closer monitoring (69)
Identification of imbalances in other inflammatory markers that predict severity
and/or frequency of VOCs are needed in order to identify potential therapeutic
targets and treatments.
18

Genetic Predictors of VOC
There are a number of polymorphisms in the β-hemoglobin gene. While
hemolytic anemia and VOC occur with all variants, some genotypes are
associated with more severe disease than others, in part due to varying cellular
concentrations of HbS and hence the degree of polymer formation (70).
Determining the genotypic variant present in an individual could help to predict
the severity of disease. Other genetic mutations have also been associated with
increased frequency of VOCs. The presence of both single nucleotide
polymorphisms +191 and +292 in LGALS3 resulting in intermediate serum
galectin-3 levels have been associated with a higher frequency of VOCs (71).

Higher levels of fetal hemoglobin are thought to be protective against VOC
(56,57). A recent study suggested that introduction of mutations into the γ-globin
gene promoter disrupted binding of two major fetal globin repressors, BC11A and
ZBTB7A. This may result in increased expression of fetal hemoglobin and thus
help to prevent VOC (72). Genome-editing technologies may therefore allow for
new strategies in management of patients with SCD at risk of frequent VOCs.

Preventive Pharmacotherapy
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Hydroxyurea is one of the most commonly used drugs for management of painful
crises in adult patients with sickle cell anemia. It is indicated for reduction of the
frequency of painful crises and to reduce the need for blood transfusions in adult
patients with sickle cell anemia with recurrent moderate to severe painful crises
(generally at least three VOCs during the preceding 3 months) (45). In addition,
NHLBI also recommends its use in patients who have pain that interferes with
daily activities or quality of life, as well as in patients with a history of severe or
recurrent ACS or severe chronic anemia that interferes with daily activities or
quality of life, and in infants >9 months of age, children, and adolescents to
reduce the incidence of SCD-related complications (45). Hydroxyurea has been
shown to increase levels of fetal hemoglobin, which appears to be protective
against VOC (73,74). In addition, hydroxyurea treatment has been associated
with lower white blood cell, platelet and reticulocyte, and dense-cell counts; lower
levels of adherent reticulocytes and leukocytes that may release proinflammatory cytokines may also help to prevent initiation of VOC (73–75). Most
importantly, hydroxyurea has been shown to reduce the number of pain episodes
in adults with sickle cell anemia, with an annual rate of VOC 44% lower than
placebo (P<0.001) (74). A 9-year follow-up study indicated that hydroxyurea also
reduced mortality by 40% (73). The optimal response to hydroxyurea occurs
when the dose is titrated to a maximum tolerated dose that induces mild
myelosuppression, with individual pharmacokinetics, pharmacodynamics, and
pharmacogenomics contributing to the variability (76). As a result, there may be
limitations to its effectiveness, especially in clinical practice. While hydroxyurea is
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generally well tolerated, some patients experience mild and reversible cytopenias
leading to temporary suspension of treatment. A number of recognized and
potential adverse events, many of which are rare, have been reported with
hydroxyurea, including skin ulcers, pancytopenia, diarrhea, rash, vomiting,
nausea, anorexia, and thrombocytopenia that may cause some patients to
discontinue treatment (76). Misconceptions about hydroxyurea-associated side
effects and poor adherence are the greatest barriers to the use of and efficacy of
hydroxyurea (77).

Although less well established, a number of other possible treatments for
management of patients with frequent VOCs have been approved or are in
development. Studies have shown that supplementation with L-glutamine
decreases endothelial cell adhesion, suggesting that it may be useful for
prevention of VOC (78); L-glutamine was approved by the FDA in 2017 to reduce
the complications of SCD in adult and pediatric patients 5 years of age and older
(79). This approval was based on a clinical trial in 230 patients who had had at
least two or more painful crises in the previous 12 months; all patients were
stable on hydroxyurea for at least 3 months and continued treatment throughout
the study. Over the course of the 48-week study, patients randomized to Lglutamine had fewer sickle cell crises (3 vs 4), fewer hospitalizations for sickle
cell pain (2 vs 3), and fewer cumulative days in the hospital (6.5 days vs 11.0
days) than in those randomized to placebo, respectively. The median time to the
first sickle cell crisis was 84 days for patients who received L-glutamine and 54
21

days for those who received placebo. There were also fewer occurrences of ACS
in patients randomized to L-glutamine than placebo (8.6% vs 23.1%) (79).

Crizanlizumab has been approved to reduce the frequency of VOCs in patients
aged 16 years and older (80). This humanized immunoglobulin G2 (IgG2)
antibody inhibits P-selectin and blocks its interaction with its ligands, including Pselectin glycoprotein ligand 1 (PSGL-1), thereby reducing VOC (81). In a phase
2, multicenter, randomized, placebo-controlled trial in patients aged 16–65 years,
crizanlizumab 5 mg/kg administered every 4 weeks (after a loading dose 2 weeks
apart) with or without hydroxyurea was associated with a significantly lower
annual rate of VOCs than placebo (1.6 vs 3.0, P=0.01) and a significantly longer
time to first crisis than placebo (4.1 vs 1.4 months, P=0.001) (81). In a post hoc
subgroup analysis of patients in the SUSTAIN trial who were VOC free during the
study, more patients were event-free in the crizanlizumab 5 mg/kg arm versus
placebo, including patients with more frequent VOCs (ie, 5–10; 28.0% vs 4.2%),
those who had the HbSS genotype (31.9% vs 17.0%), and those using
hydroxyurea concomitantly (33.3% vs 17.5%) (82).

Another potential therapy currently under clinical development is the
investigational oral agent voxelotor (GBT440). GBT440 is an allosteric modulator
of hemoglobin-oxygen affinity, thus holding HbS in the oxygenated state,
improving the rheology and hemodynamics of blood, and possibly delaying
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polymerization and inhibiting RBC sickling (83). Phase 2 studies have
demonstrated improvements in hemoglobin levels and hemolysis (84). Results
from the phase 3 HOPE study of voxelotor in patients with SCD (N=274) showed
a significant increase in the proportion of patients with a hemoglobin increase >1
g/dL (primary endpoint) with the 1500 mg dose (51%; P<0.001) compared with
placebo (7%) after 24 weeks of treatment (85). However, there was only a trend
towards a reduction in the annualized incidence rate of VOC between voxelotor
and placebo in this study; additional research and follow-up is required to
determine the effect of voxelotor on the frequency of VOC events (85). Voxelotor
was generally safe and well tolerated with a safety profile similar to that of
placebo; there was also no substantial differences in the percentage of patients
with sickle cell disease-related adverse events (85).

Treatment of pain, especially chronic pain, with opioids does not address the
underlying disease processes, and may lead to hyperalgesia, dependence, and
tolerance (86). Indeed, opioids may adversely affect the membrane structure of
RBCs, increase mast cell degranulation-induced inflammation, and activation of
tyrosine kinases, all of which may contribute to VOC (86). Prevention of pain
associated with VOC is a preferred approach whenever possible. Avoidance of
VOC triggers such as cold, fatigue, and stress can help to reduce the frequency
of VOCs (58,87). Another prevention strategy is avoidance of agents that may
lead to initiation of VOC. For example, animal studies have suggested that vasoconstrictive agents such as α-adrenergic receptor agonists (including
23

phenylephrine) may precipitate VOC (88). Such agents should therefore be
avoided in patients with SCD.

Conclusions
Vaso-occlusive crisis in patients with SCD is a multifactorial process
characterized by inflammation, adhesion, and multicellular aggregation of sickled
RBCs, endothelial cells, platelets, and other blood cells, resulting in vasoocclusion and acute severe pain. While management protocols to abort or
ameliorate VOC by administration of opioids have been developed, the focus
should shift to prevention of onset and reduction in frequency of pain crises,
especially in those at higher risk. Research has identified a number of
quantitative leads for identifying those patients at high risk of VOC. These
patients may be good candidates for therapies in combination with hydroxyurea,
such as L-glutamine, and crizanlizumab, which take advantage of the underlying
mechanisms of VOC and are able to reduce the frequency of this debilitating
consequence of SCD.
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Table 1. Risk factors associated with VOCs and other SCD-related complications
(24,27,46,59–72)
Triggers

Patient factors: hypoxia, infection, fever, acidosis, dehydration,
pregnancy, menstruation, obstructive sleep apnea, pain, anxiety,
depression, alcohol consumption, physical exhaustion
(46,59,60,70)
Environmental factors: exposure to temperature extremes, high
wind speed and humidity (46,59,61)
Comorbidities: sarcoidosis, diabetes, cholecystitis, herpes (59)

Biomarkers

Blood parameters: high platelet and neutrophil counts, high
hemoglobin levels, unbound extracellular hemoglobin, increased
levels of plasma platelet factors 3 and 4, platelet hyperactivity
(24,27,62–64)
Serum factors: high lactate dehydrogenase levels, elevated
levels of fractal kinase and fractalkine (Fkn) gene expression
(65,68)
Inflammatory factors: reduced interleukin 10 (IL-10) secretion,
levels levels of soluble CD163 >1400 ng/mL, secretory
phospholipase A2 (65–67,69)

Genetic
predictors

Single nucleotide polymorphisms: +191 and +292 in galectin-3
gene (LGALS3) (71)
Mutations in the γ-globin gene promoter that disrupt binding of
major fetal globin repressors (72)

[footnote to table]
SCD, sickle cell disease; VOC, vaso-occlusive crisis.
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